Volker Limmroth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Volker Limmroth has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Hans-Christoph Diener
Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Faculty of Medicine, University Duisburg-Essen, Essen, Germany
14 shared publications Hans-Christoph Diener
University Hospital Essen
3 shared publicationsZaza Katsarava
3 shared publicationsH. C. Diener
Department of Neurology,1University Hospital Essen, Hufelandstr 55, Essen, Merck, Sharpe and Dohme GmbH Germany,2Lindenplatz, Haar, Germany
2 shared publicationsH. Kaube
2 shared publications- Zaza Katsarava
Evangelical Hospital Unna, Unna, Germany
2 shared publications
Latest Publications
- 9 September 2009
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 36 (07) , 331-333
Versorgungsnetzwerke für innovative Immuntherapien
Monoklonale Antikörper erweitern das Therapiespektrum in der Behandlung von Patienten mit Multipler Sklerose. Weitere Zulassungen innovativer Immuntherapien sind in naher Zukunft zu erwarten. Aufgrund der steigenden Zahl von PML-Fällen, des Risikos anaphylaktischer Reaktionen sowie hoher Therapiekosten bei der Anwendung von Natalizumab sind besondere Anforderungen nicht nur an die Organisations- und Prozessstandards der durchführenden Einrichtungen, sondern auch an die Kooperationsqualität der Zentren zu stellen. Auf Initiative der DMSG und der neurologischen Berufsverbände wird hiermit ein Vorschlag zur Gründung von Versorgungsnetzwerken für innovative Immuntherapien unterbreitet, der Patienten den Zugang zu diesen Therapien bei höchstmöglicher Sicherheit bieten soll. Monoclonal antibodies have extended the therapeutic options in the treatment of patients with multiple sclerosis. Further approvals of innovative immune therapies are expected in the near future. Due to the increasing numbers of cases of PML in natalizumab patients and the risk of hypersensitivity reactions as well as the high therapy costs, there is not only a need to define standards regarding organisational and process quality in treating centres, but also to create standards that direct the cooperation between the centres. On the initiative of the German MS Society (DMSG) and the Neurologists Associations, the following proposal is being presented concerning the creation of networks for medical care with innovative immune therapies. These networks have the purpose to help patients obtain access to novel therapies and ensure at the same time the best possible safety.
- 9 September 2009
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 36 (07) , 331-333
Versorgungsnetzwerke für innovative Immuntherapien
Monoklonale Antikörper erweitern das Therapiespektrum in der Behandlung von Patienten mit Multipler Sklerose. Weitere Zulassungen innovativer Immuntherapien sind in naher Zukunft zu erwarten. Aufgrund der steigenden Zahl von PML-Fällen, des Risikos anaphylaktischer Reaktionen sowie hoher Therapiekosten bei der Anwendung von Natalizumab sind besondere Anforderungen nicht nur an die Organisations- und Prozessstandards der durchführenden Einrichtungen, sondern auch an die Kooperationsqualität der Zentren zu stellen. Auf Initiative der DMSG und der neurologischen Berufsverbände wird hiermit ein Vorschlag zur Gründung von Versorgungsnetzwerken für innovative Immuntherapien unterbreitet, der Patienten den Zugang zu diesen Therapien bei höchstmöglicher Sicherheit bieten soll. Monoclonal antibodies have extended the therapeutic options in the treatment of patients with multiple sclerosis. Further approvals of innovative immune therapies are expected in the near future. Due to the increasing numbers of cases of PML in natalizumab patients and the risk of hypersensitivity reactions as well as the high therapy costs, there is not only a need to define standards regarding organisational and process quality in treating centres, but also to create standards that direct the cooperation between the centres. On the initiative of the German MS Society (DMSG) and the Neurologists Associations, the following proposal is being presented concerning the creation of networks for medical care with innovative immune therapies. These networks have the purpose to help patients obtain access to novel therapies and ensure at the same time the best possible safety.
- Open Access
- 15 July 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 77
Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy
Cisplatin mediates its antineoplastic activity by formation of distinct DNA intrastrand cross links. The clinical efficacy and desirable dose escalations of cisplatin are restricted by the accumulation of DNA lesions in dorsal root ganglion (DRG) cells leading to sensory polyneuropathy (PNP). We investigated in a mouse model by which mechanism recombinant erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional damage caused by cisplatin treatment with special emphasis on DNA damage burden.A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p < 0,001). The co-application of rhEPO, however, did not alter the level of unrepaired cisplatin-DNA lesions accumulating in DRG target cells. Micro-morphological analyses of the sciatic nerve from cisplatin-exposed mice showed damaged myelin sheaths and mitochondria. Co-administered rhEPO inhibited myelin sheaths from structural injuries and resulted in an increased number of intact mitochondria.The protective effect of recombinant erythropoietin is not mediated by reducing the burden of DNA platination in the target cells, but it is likely to be due to a higher resistance of the target cells to the adverse effect of DNA damage. The increased frequency of intact mitochondria might also contribute to this protective role.
- 15 July 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 77
Open AccessErythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy
Cisplatin mediates its antineoplastic activity by formation of distinct DNA intrastrand cross links. The clinical efficacy and desirable dose escalations of cisplatin are restricted by the accumulation of DNA lesions in dorsal root ganglion (DRG) cells leading to sensory polyneuropathy (PNP). We investigated in a mouse model by which mechanism recombinant erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional damage caused by cisplatin treatment with special emphasis on DNA damage burden.A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p < 0,001). The co-application of rhEPO, however, did not alter the level of unrepaired cisplatin-DNA lesions accumulating in DRG target cells. Micro-morphological analyses of the sciatic nerve from cisplatin-exposed mice showed damaged myelin sheaths and mitochondria. Co-administered rhEPO inhibited myelin sheaths from structural injuries and resulted in an increased number of intact mitochondria.The protective effect of recombinant erythropoietin is not mediated by reducing the burden of DNA platination in the target cells, but it is likely to be due to a higher resistance of the target cells to the adverse effect of DNA damage. The increased frequency of intact mitochondria might also contribute to this protective role.
- 22 February 2006
- Published by Hindawi Limited
- Vol. 60 (3) , 295-299
Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany
The prevalence of migraine in Germany is up to 14% in the female and up to 8% in the male population and peaks between the age of 35 and 45. Few studies have investigated the productivity loss and resulting costs attributable to migraine in Germany or addressed the question whether these costs can be reduced by optimal treatment. In recent years, 5‐HT1B/D agonists (so‐called triptans), a generation of drugs highly specific for migraine treatment, have been introduced. Seven 5‐HT1B/D agonists have been approved in Germany with more than 20 dosage forms. We present a model that enables employers to estimate the annual cost of migraine and the annual cost that could be saved by treatment of migraine with rizatriptan compared with the use of non‐specific antimigraine medication. A representative German company with 10,000 employees is used for the reference case analysis. This company is predicted to have 580 female and 284 male employees with migraine. These employees are estimated to lose 6992 workdays or 31.8 person years of productive effort annually due to migraine, valued approximately 1,431,719 euros. The value of work loss that could be avoided by treating migraine with rizatriptan is estimated at 619,094 euros annually. These data indicate that costs arising from lost productivity can be reduced by treating migraine headaches with a triptan.
- 22 February 2006
- Published by Hindawi Limited
- Vol. 60 (3) , 295-299
Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany
The prevalence of migraine in Germany is up to 14% in the female and up to 8% in the male population and peaks between the age of 35 and 45. Few studies have investigated the productivity loss and resulting costs attributable to migraine in Germany or addressed the question whether these costs can be reduced by optimal treatment. In recent years, 5‐HT1B/D agonists (so‐called triptans), a generation of drugs highly specific for migraine treatment, have been introduced. Seven 5‐HT1B/D agonists have been approved in Germany with more than 20 dosage forms. We present a model that enables employers to estimate the annual cost of migraine and the annual cost that could be saved by treatment of migraine with rizatriptan compared with the use of non‐specific antimigraine medication. A representative German company with 10,000 employees is used for the reference case analysis. This company is predicted to have 580 female and 284 male employees with migraine. These employees are estimated to lose 6992 workdays or 31.8 person years of productive effort annually due to migraine, valued approximately 1,431,719 euros. The value of work loss that could be avoided by treating migraine with rizatriptan is estimated at 619,094 euros annually. These data indicate that costs arising from lost productivity can be reduced by treating migraine headaches with a triptan.
- 1 December 2005
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 9 (6) , 430-435
Medication-overuse headache
Medication-overuse headache (MOH) can be caused by almost all anti-headache drugs including analgesics, ergots, triptans, and combined preparations The prevalence of chronic daily headache (CDH) appears to be between 2% and 4% in the general population. Current epidemiologic studies suggest that MOH accounts for approximately 50% of these cases. The pathophysiology of MOH remains unclear. The only therapy is withdrawal from the overused substances. Prednisone decreases the duration of headache in the first days of withdrawal therapy. The only strategy to reduce the prevalence of MOH is to prevent the development of MOH in the first place by restriction of anti-headache drugs and constant education of patients.
- 1 December 2005
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 9 (6) , 430-435
Medication-overuse headache
Medication-overuse headache (MOH) can be caused by almost all anti-headache drugs including analgesics, ergots, triptans, and combined preparations The prevalence of chronic daily headache (CDH) appears to be between 2% and 4% in the general population. Current epidemiologic studies suggest that MOH accounts for approximately 50% of these cases. The pathophysiology of MOH remains unclear. The only therapy is withdrawal from the overused substances. Prednisone decreases the duration of headache in the first days of withdrawal therapy. The only strategy to reduce the prevalence of MOH is to prevent the development of MOH in the first place by restriction of anti-headache drugs and constant education of patients.
- Open Access
- 1 November 2005
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 44 (11) , 1373
Cerebral MRI is necessary in patients with rheumatoid arthritis and uveitis before undergoing therapy with TNF-α blocking agents
Optic neuritis (ON) is often the first symptom of further demyelinating events within the central nervous system (CNS), eventually developing into multiple sclerosis (MS). As for rheumatoid arthritis (RA), TNF-α was considered to be the key mediator of the inflammatory response in autoimmune CNS disorders, such as MS. Subsequently, TNF-α-blocking agents were suggested as potential therapies for MS and related disorders. However, large clinical trials in patients with MS revealed that TNF-α-blocking agents, such as lenercept, cause an increase in both relapse rates and MRI lesion load. A recent study from our group suggests that up to 30% of patients with uveitis carry clinically silent inflammatory lesions at the time of presentation, as visualized by MRI, suggestive of a chronic inflammatory disorder of the CNS.
- 1 November 2005
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 44 (11) , 1373
Open AccessCerebral MRI is necessary in patients with rheumatoid arthritis and uveitis before undergoing therapy with TNF-α blocking agents
Optic neuritis (ON) is often the first symptom of further demyelinating events within the central nervous system (CNS), eventually developing into multiple sclerosis (MS). As for rheumatoid arthritis (RA), TNF-α was considered to be the key mediator of the inflammatory response in autoimmune CNS disorders, such as MS. Subsequently, TNF-α-blocking agents were suggested as potential therapies for MS and related disorders. However, large clinical trials in patients with MS revealed that TNF-α-blocking agents, such as lenercept, cause an increase in both relapse rates and MRI lesion load. A recent study from our group suggests that up to 30% of patients with uveitis carry clinically silent inflammatory lesions at the time of presentation, as visualized by MRI, suggestive of a chronic inflammatory disorder of the CNS.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , P362
Risiko von Myelodysplastischen Syndromen (MDS) unter Langzeittherapie mit AZA bei Multipler Sklerose
Azathioprin (AZA) ist ein häufig eingesetztes Immunsuppressivum bei Multipler Sklerose (MS). Die Wirksamkeit im Vergleich zu immunmodulatorischen Therapien wie Interferon Beta (IFNB) ist unklar. Konzepte für Kombinationstherapien aus AZA und IFNB wurden entwickelt. Ein erhöhtes Risiko für die Entwicklung solider Tumoren unter hohen AZA Kumulativdosen (KD) ist wahrscheinlich. Beim MDS handelt es sich um eine seltene klonale Stammzellerkrankung (Inzidenz 1/100.000 pro 10 Jahre in der Altersgruppe 40–50), gekennzeichnet durch Veränderungen der Hämatopoese und Cytopenie. Sekundäre Formen (sMDS) z.B. nach Chemotherapie sind bekannt. In einer aktuellen Studie bestand ein 100-fach erhöhtes Risiko für die Entwicklung von sMDS bei Patienten, die wegen nicht-maligner Erkrankungen mit AZA behandelt worden sind. Das mediane Überleben betrug dabei nur 9 Monate. Methodik: Fragebögen wurden an 636 MS Patienten unserer Klinik. Diejenigen mit AZA Exposition wurde so identifiziert. Differentialblutbilder (DBB) wurden für alle Patienten beschafft und analysiert. Resultat: 47% der Fragebögen wurden retourniert (n=299, mittleres Alter 44.8 Jahre). 69 Patienten sind mit AZA behandelt worden (mittleres Alter 45.6, mittlere KD 268g, zwischen 19.5–1050g). Wir identifizierten 1 MS Patientin (45 Jahre, KD 627g), mir der Diagnose eines sMDS und nachfolgender Knochenmarktransplantation. Die DBB aller weiteren Patienten waren unverdächtig. 5 zusätzliche Malignome wurden in der AZA Gruppe (n=69) dokumentiert (Oropharynx, Skrotum, Mamma, Uterus), ebenso 5 in der viel größeren nicht-AZA Gruppe (n=230, 3 Mamma Carcinome, Hodgkin Lymphom, AML). Die mittlere KD war in der Gruppe der Malignompatienten höher als in der Gruppe ohne Neoplasien. Schlussfolgerung: Wir identifizierten einen AZA-assoziierten sMDS Fall in einer eher kleinen Kohorte von MS Patienten mit AZA Therapie. Dies ist ein bemerkenswertes Ergebnis ist, da die MDS Inzidenz in der untersuchten Altersgruppe normalerweise extrem gering ist. Wir ergänzen damit eine andere Studie, die ein erhebliches Risiko für AZA-assoziierte sMDS fand, mit Daten für die MS Population. Alle Fälle unklarer Cytopenien unter AZA sollten vollständig abgeklärt werden, da die Prognose ohne Therapie äusserst schlecht ist. Die Prävalenz von Malignomen war assoziiert mit einer höheren KD und zudem signifikant höher als in der nicht-AZA Gruppe, was mit älteren Daten übereinstimmt. Wir bezweifeln, dass AZA zur Langzeittherapie bei MS geeignet ist.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , P362
Risiko von Myelodysplastischen Syndromen (MDS) unter Langzeittherapie mit AZA bei Multipler Sklerose
Azathioprin (AZA) ist ein häufig eingesetztes Immunsuppressivum bei Multipler Sklerose (MS). Die Wirksamkeit im Vergleich zu immunmodulatorischen Therapien wie Interferon Beta (IFNB) ist unklar. Konzepte für Kombinationstherapien aus AZA und IFNB wurden entwickelt. Ein erhöhtes Risiko für die Entwicklung solider Tumoren unter hohen AZA Kumulativdosen (KD) ist wahrscheinlich. Beim MDS handelt es sich um eine seltene klonale Stammzellerkrankung (Inzidenz 1/100.000 pro 10 Jahre in der Altersgruppe 40–50), gekennzeichnet durch Veränderungen der Hämatopoese und Cytopenie. Sekundäre Formen (sMDS) z.B. nach Chemotherapie sind bekannt. In einer aktuellen Studie bestand ein 100-fach erhöhtes Risiko für die Entwicklung von sMDS bei Patienten, die wegen nicht-maligner Erkrankungen mit AZA behandelt worden sind. Das mediane Überleben betrug dabei nur 9 Monate. Methodik: Fragebögen wurden an 636 MS Patienten unserer Klinik. Diejenigen mit AZA Exposition wurde so identifiziert. Differentialblutbilder (DBB) wurden für alle Patienten beschafft und analysiert. Resultat: 47% der Fragebögen wurden retourniert (n=299, mittleres Alter 44.8 Jahre). 69 Patienten sind mit AZA behandelt worden (mittleres Alter 45.6, mittlere KD 268g, zwischen 19.5–1050g). Wir identifizierten 1 MS Patientin (45 Jahre, KD 627g), mir der Diagnose eines sMDS und nachfolgender Knochenmarktransplantation. Die DBB aller weiteren Patienten waren unverdächtig. 5 zusätzliche Malignome wurden in der AZA Gruppe (n=69) dokumentiert (Oropharynx, Skrotum, Mamma, Uterus), ebenso 5 in der viel größeren nicht-AZA Gruppe (n=230, 3 Mamma Carcinome, Hodgkin Lymphom, AML). Die mittlere KD war in der Gruppe der Malignompatienten höher als in der Gruppe ohne Neoplasien. Schlussfolgerung: Wir identifizierten einen AZA-assoziierten sMDS Fall in einer eher kleinen Kohorte von MS Patienten mit AZA Therapie. Dies ist ein bemerkenswertes Ergebnis ist, da die MDS Inzidenz in der untersuchten Altersgruppe normalerweise extrem gering ist. Wir ergänzen damit eine andere Studie, die ein erhebliches Risiko für AZA-assoziierte sMDS fand, mit Daten für die MS Population. Alle Fälle unklarer Cytopenien unter AZA sollten vollständig abgeklärt werden, da die Prognose ohne Therapie äusserst schlecht ist. Die Prävalenz von Malignomen war assoziiert mit einer höheren KD und zudem signifikant höher als in der nicht-AZA Gruppe, was mit älteren Daten übereinstimmt. Wir bezweifeln, dass AZA zur Langzeittherapie bei MS geeignet ist.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , P425
A novel method of pain related potentials elicited by electrical stimulation of skin for early detection of diabetic small-fiber neuropathy
Objective: To investigate whether pain related evoked potentials (PREP) elicited by non-invasive trans-cutaneous electrical stimulation could be useful in detection of diabetic small fiber neuropathy. Methods: We studied two groups of healthy controls ('young': N=36, 8 females, mean age=22 years, range [19–29], 'older': N=24, 14 females, mean age=46.5 years, range [30–65]) and two groups of patients with diabetes (‘with neuropathic symptoms': N=35, 15 females, mean age=52 years, range [36–64] and 'without symptoms': N=24, 8 females, range [32–64]). We included only diabetic patients without any abnormalities in routine nerve conduction studies. We investigated PREP over Cz vs. earlobes and measured latencies (ms) and NP peak-to-peak amplitudes (µV). Results: Latencies and amplitudes did not differ between 'young' controls (right arm 148±13ms, 30±12µV; left arm 149±11ms, 29±10µV; right leg 177±12ms, 25±9µV; left leg 175±15ms, 24±7µV) and 'older' controls (right arm 149±7ms, 27±12µV; left arm 148±9ms, 30±11µV; right leg 184±16ms, 22±9µV; left leg 179±15ms, 21±8µV). In patients with neuropathic symptoms we found an increase in latencies and decrease in amplitudes from upper limbs (right arm 176±27ms, 20±12µV, left arm 176±30ms, 21±13µV) and lower limbs (right leg 224±25ms, 16±7µV; left leg 217±24ms, 15±9µV). In patients without symptoms we observed an increase of latencies and decrease of amplitudes from lower limbs (right leg 203±27ms, 18±7µV; left leg 198±28ms, 19±8µV), while PREP form arms were normal (right arm 156±19ms, 28±13µV, left arm 153±18ms, 26±10µV). Conclusions: This novel technique was sensitive in detecting abnormalities of peripheral nerve function in the early phase of diabetes while the standard nerve conduction studies were normal. In summary, the method is cheap, non-invasive, easy to perform and could be widely used in addition to the routine electrophysiological methods for early detection of small fiber neuropathies.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , P425
A novel method of pain related potentials elicited by electrical stimulation of skin for early detection of diabetic small-fiber neuropathy
Objective: To investigate whether pain related evoked potentials (PREP) elicited by non-invasive trans-cutaneous electrical stimulation could be useful in detection of diabetic small fiber neuropathy. Methods: We studied two groups of healthy controls ('young': N=36, 8 females, mean age=22 years, range [19–29], 'older': N=24, 14 females, mean age=46.5 years, range [30–65]) and two groups of patients with diabetes (‘with neuropathic symptoms': N=35, 15 females, mean age=52 years, range [36–64] and 'without symptoms': N=24, 8 females, range [32–64]). We included only diabetic patients without any abnormalities in routine nerve conduction studies. We investigated PREP over Cz vs. earlobes and measured latencies (ms) and NP peak-to-peak amplitudes (µV). Results: Latencies and amplitudes did not differ between 'young' controls (right arm 148±13ms, 30±12µV; left arm 149±11ms, 29±10µV; right leg 177±12ms, 25±9µV; left leg 175±15ms, 24±7µV) and 'older' controls (right arm 149±7ms, 27±12µV; left arm 148±9ms, 30±11µV; right leg 184±16ms, 22±9µV; left leg 179±15ms, 21±8µV). In patients with neuropathic symptoms we found an increase in latencies and decrease in amplitudes from upper limbs (right arm 176±27ms, 20±12µV, left arm 176±30ms, 21±13µV) and lower limbs (right leg 224±25ms, 16±7µV; left leg 217±24ms, 15±9µV). In patients without symptoms we observed an increase of latencies and decrease of amplitudes from lower limbs (right leg 203±27ms, 18±7µV; left leg 198±28ms, 19±8µV), while PREP form arms were normal (right arm 156±19ms, 28±13µV, left arm 153±18ms, 26±10µV). Conclusions: This novel technique was sensitive in detecting abnormalities of peripheral nerve function in the early phase of diabetes while the standard nerve conduction studies were normal. In summary, the method is cheap, non-invasive, easy to perform and could be widely used in addition to the routine electrophysiological methods for early detection of small fiber neuropathies.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , V141
Central sensitisation and activation of serotonin uptake in patients with medication overuse headache
Background: Central sensitization of pain processing may play pivotal role in the pathophysiology of medication overuse headache (MOH). One possible mechanism include alteration of the anti-nociceptive serotonergic neurons. Objective: To investigate central pain processing and serotonin changes in MOH. Methods: Healthy controls (n=18) and patients with episodic migraine (n=16), analgesic-induced headache (n=15) and triptan-induced headache (n=15) were studied both, before and after withdrawal. Patients with co-existing depression (BDI>21) were excluded. The nociceptive blink reflex (nBR) and pain related potentials (PRP) were recorded following stimulation of the forehead and hand. Kinetics of serotonin uptake in platelets was measured. Results: In patients with MOH we found a facilitation of trigeminal nociceptive potentials (but not of blink reflex responses) and increase of serotonin uptake which normalized after withdrawal. There were no differences between patients overusing analgesics and those overusing triptans. Patients with episodic migraine did not differ from controls. Conclusion: Augmentation of PRP but not of nBR indicates the leading role of supra-spinal nociceptive structures in processes of headache chronification. Increase of serotonin uptake in both analgesic and triptan induced MOH seems to be a consequence of a high headache frequency rather than a major underlying pathophysiological mechanism.
- 26 October 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (S 4) , V141
Central sensitisation and activation of serotonin uptake in patients with medication overuse headache
Background: Central sensitization of pain processing may play pivotal role in the pathophysiology of medication overuse headache (MOH). One possible mechanism include alteration of the anti-nociceptive serotonergic neurons. Objective: To investigate central pain processing and serotonin changes in MOH. Methods: Healthy controls (n=18) and patients with episodic migraine (n=16), analgesic-induced headache (n=15) and triptan-induced headache (n=15) were studied both, before and after withdrawal. Patients with co-existing depression (BDI>21) were excluded. The nociceptive blink reflex (nBR) and pain related potentials (PRP) were recorded following stimulation of the forehead and hand. Kinetics of serotonin uptake in platelets was measured. Results: In patients with MOH we found a facilitation of trigeminal nociceptive potentials (but not of blink reflex responses) and increase of serotonin uptake which normalized after withdrawal. There were no differences between patients overusing analgesics and those overusing triptans. Patients with episodic migraine did not differ from controls. Conclusion: Augmentation of PRP but not of nBR indicates the leading role of supra-spinal nociceptive structures in processes of headache chronification. Increase of serotonin uptake in both analgesic and triptan induced MOH seems to be a consequence of a high headache frequency rather than a major underlying pathophysiological mechanism.
- 16 August 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (08) , 463-471
Topiramat zur Prophylaxe von Kopfschmerzen
In drei großen plazebokontrollierten randomisierten Studien konnte die Wirksamkeit von Topiramat zur Prophylaxe der Migräne belegt werden. Dabei zeigte sich, dass Tagesdosen zwischen 25 und 200 mg wirksam sind. Die Responderrate liegt um 50 %. Jenseits einer Tagesdosis von 100 mg nehmen allerdings die Nebenwirkungen deutlich zu, sodass empfohlen wird, in einem Dosisbereich zwischen 50 und 100 mg zu behandeln. Bei einzelnen Patienten ist aber schon eine Dosis von 25 mg wirksam. Als häufigste aber meist transiente und leicht ausgeprägte Nebenwirkung wurden Parästhesien beobachtet. Andere Nebenwirkungen, die zum Teil zum Studienabbruch führten, umfassen Schlafstörungen, Appetitlosigkeit, Gedächtnisstörungen, Müdigkeit, Angstgefühle und Wortfindungsstörungen. Treten deutliche Wortfindungsstörungen auf, muss die Substanz abgesetzt werden. Topiramat zeigt auch in einigen offenen und einer plazebokontrollierten Studie eine Wirksamkeit beim Cluster-Kopfschmerz. Die Erfahrung der Autoren zeigt, dass aber bei einem Teil der Clusterpatienten höhere Dosierungen als bei der Migräne verwendet werden müssen. Derzeit werden randomisierte Studien mit Topiramat bei Patienten mit chronischer Migräne mit und ohne medikamenteninduzierten Dauerkopfschmerz durchgeführt. Patients with frequent migraine attacks need prophylactic treatment. Topiramate was superior to placebo in 3 randomised trials for preventive migraine therapy. Effective doses range between 25 and 200 mg. Response rates yield up to 50 %. Doses > 100 mg lead to an increase in side effects, hence dose between 50 and 100 mg are recommended as standard doses. In single patients doses of 25 mg were shown to be effective. Adverse events include paraesthesia, insomnia, loss of appetite, dizziness, anxiety and difficulties in word retrieval. In cases of severe word retgrieval topiramate should be discontinued. Topiramate may also be effective in the prophylactic treatment of cluster headache. Effective doses appear to be higher than the ones used in migraine. The treatment of chronic migraine with and without medication overuse headache with topiramate is currently investigated in 2 prospective placebo-controlled trials.
- 16 August 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (08) , 463-471
Topiramat zur Prophylaxe von Kopfschmerzen
In drei großen plazebokontrollierten randomisierten Studien konnte die Wirksamkeit von Topiramat zur Prophylaxe der Migräne belegt werden. Dabei zeigte sich, dass Tagesdosen zwischen 25 und 200 mg wirksam sind. Die Responderrate liegt um 50 %. Jenseits einer Tagesdosis von 100 mg nehmen allerdings die Nebenwirkungen deutlich zu, sodass empfohlen wird, in einem Dosisbereich zwischen 50 und 100 mg zu behandeln. Bei einzelnen Patienten ist aber schon eine Dosis von 25 mg wirksam. Als häufigste aber meist transiente und leicht ausgeprägte Nebenwirkung wurden Parästhesien beobachtet. Andere Nebenwirkungen, die zum Teil zum Studienabbruch führten, umfassen Schlafstörungen, Appetitlosigkeit, Gedächtnisstörungen, Müdigkeit, Angstgefühle und Wortfindungsstörungen. Treten deutliche Wortfindungsstörungen auf, muss die Substanz abgesetzt werden. Topiramat zeigt auch in einigen offenen und einer plazebokontrollierten Studie eine Wirksamkeit beim Cluster-Kopfschmerz. Die Erfahrung der Autoren zeigt, dass aber bei einem Teil der Clusterpatienten höhere Dosierungen als bei der Migräne verwendet werden müssen. Derzeit werden randomisierte Studien mit Topiramat bei Patienten mit chronischer Migräne mit und ohne medikamenteninduzierten Dauerkopfschmerz durchgeführt. Patients with frequent migraine attacks need prophylactic treatment. Topiramate was superior to placebo in 3 randomised trials for preventive migraine therapy. Effective doses range between 25 and 200 mg. Response rates yield up to 50 %. Doses > 100 mg lead to an increase in side effects, hence dose between 50 and 100 mg are recommended as standard doses. In single patients doses of 25 mg were shown to be effective. Adverse events include paraesthesia, insomnia, loss of appetite, dizziness, anxiety and difficulties in word retrieval. In cases of severe word retgrieval topiramate should be discontinued. Topiramate may also be effective in the prophylactic treatment of cluster headache. Effective doses appear to be higher than the ones used in migraine. The treatment of chronic migraine with and without medication overuse headache with topiramate is currently investigated in 2 prospective placebo-controlled trials.
- 16 August 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (08) , 451-462
Spezifische Therapie der akuten Migräneattacke: Mutterkornalkaloide und Triptane
Diese Arbeit referiert die Ergebnisse kontrollierter Studien zur Therapie akuter Migräneattacken mit spezifischen Migränemitteln wie Mutterkornalkaloiden und Triptanen. Vergleichsstudien sind möglich als direkter Vergleich zweier Substanzen oder basieren auf großen Metaanalysen. Die meisten Studien benutzten eine Besserung der Kopfschmerzen zwei Stunden nach Einnahme des Migränemittels von schwer oder mittelschwer auf leichte oder keine Kopfschmerzen als den primären Zielparameter. Die Internationale Kopfschmerzgesellschaft empfiehlt aber entweder den Endpunkt „schmerzfrei nach zwei Stunden” oder „sustained pain free” zu benutzen (= schmerzfrei nach zwei Stunden, kein Wiederkehrkopfschmerz, keine zusätzliche Medikation). Mittelschwere und schwere Migräneattacken sollten mit spezifischen Migränemitteln behandelt werden. Dabei sind Triptane signifikant wirksamer als Mutterkornalkaloide. Nicht alle Triptane sind gleich wirksam. Sie unterscheiden sich in Wirksamkeit, Häufigkeit des Wiederkehrkopfschmerzes und den Nebenwirkungen. This review summarizes the results of treatment trials with ergots and 5-HT1B/D-agonists (triptans) for the treatment of acute migraine attacks. A comparison between anti-migraine drugs is only possible in randomized controlled trials (RCTs) with head-to-head comparisons. Another way to indirectly compare the different triptans is a meta-analysis. The primary endpoint in most headache trials is the improvement from severe or moderate head pain to mild or no pain after 2 hours. The most recent recommendations of the International Headache Society, however, propose 2 hour pain free and 24 hours sustained pain free (pain free after 2 hours, no rescue medication, and no recurrence) as the appropriate endpoints for clinical trials in migraine treatment. Moderate or severe migraine attacks should be treated with specific migraine drugs. These include ergot alkaloids (also called ergots) and triptans. The efficacy of ergots is lower than that of the triptans. Not all triptans are the same. Differences can be shown for efficacy, recurrence rates and side effects.
- 16 August 2005
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 32 (08) , 451-462
Spezifische Therapie der akuten Migräneattacke: Mutterkornalkaloide und Triptane
Diese Arbeit referiert die Ergebnisse kontrollierter Studien zur Therapie akuter Migräneattacken mit spezifischen Migränemitteln wie Mutterkornalkaloiden und Triptanen. Vergleichsstudien sind möglich als direkter Vergleich zweier Substanzen oder basieren auf großen Metaanalysen. Die meisten Studien benutzten eine Besserung der Kopfschmerzen zwei Stunden nach Einnahme des Migränemittels von schwer oder mittelschwer auf leichte oder keine Kopfschmerzen als den primären Zielparameter. Die Internationale Kopfschmerzgesellschaft empfiehlt aber entweder den Endpunkt „schmerzfrei nach zwei Stunden” oder „sustained pain free” zu benutzen (= schmerzfrei nach zwei Stunden, kein Wiederkehrkopfschmerz, keine zusätzliche Medikation). Mittelschwere und schwere Migräneattacken sollten mit spezifischen Migränemitteln behandelt werden. Dabei sind Triptane signifikant wirksamer als Mutterkornalkaloide. Nicht alle Triptane sind gleich wirksam. Sie unterscheiden sich in Wirksamkeit, Häufigkeit des Wiederkehrkopfschmerzes und den Nebenwirkungen. This review summarizes the results of treatment trials with ergots and 5-HT1B/D-agonists (triptans) for the treatment of acute migraine attacks. A comparison between anti-migraine drugs is only possible in randomized controlled trials (RCTs) with head-to-head comparisons. Another way to indirectly compare the different triptans is a meta-analysis. The primary endpoint in most headache trials is the improvement from severe or moderate head pain to mild or no pain after 2 hours. The most recent recommendations of the International Headache Society, however, propose 2 hour pain free and 24 hours sustained pain free (pain free after 2 hours, no rescue medication, and no recurrence) as the appropriate endpoints for clinical trials in migraine treatment. Moderate or severe migraine attacks should be treated with specific migraine drugs. These include ergot alkaloids (also called ergots) and triptans. The efficacy of ergots is lower than that of the triptans. Not all triptans are the same. Differences can be shown for efficacy, recurrence rates and side effects.